JP2016537417A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016537417A5 JP2016537417A5 JP2016552257A JP2016552257A JP2016537417A5 JP 2016537417 A5 JP2016537417 A5 JP 2016537417A5 JP 2016552257 A JP2016552257 A JP 2016552257A JP 2016552257 A JP2016552257 A JP 2016552257A JP 2016537417 A5 JP2016537417 A5 JP 2016537417A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- cancer
- antagonist
- immunogenic combination
- tumor antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361900226P | 2013-11-05 | 2013-11-05 | |
| US61/900,226 | 2013-11-05 | ||
| PCT/US2014/063516 WO2015069571A1 (en) | 2013-11-05 | 2014-10-31 | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016537417A JP2016537417A (ja) | 2016-12-01 |
| JP2016537417A5 true JP2016537417A5 (enExample) | 2019-02-21 |
| JP6535337B2 JP6535337B2 (ja) | 2019-06-26 |
Family
ID=51987459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552257A Active JP6535337B2 (ja) | 2013-11-05 | 2014-10-31 | 腫瘍抗原を発現するポックスウイルスならびに免疫チェックポイント阻害剤のアンタゴニスト及び／またはアゴニストにより癌を治療するための組み合わせ療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20160271239A1 (enExample) |
| EP (1) | EP3065770B1 (enExample) |
| JP (1) | JP6535337B2 (enExample) |
| KR (2) | KR102395820B1 (enExample) |
| CN (1) | CN105744950A (enExample) |
| AU (1) | AU2014347004B2 (enExample) |
| CA (1) | CA2928199C (enExample) |
| DK (1) | DK3065770T3 (enExample) |
| IL (1) | IL245219B (enExample) |
| NZ (1) | NZ719232A (enExample) |
| RU (1) | RU2714142C2 (enExample) |
| WO (1) | WO2015069571A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201315321D0 (en) * | 2013-08-28 | 2013-10-09 | Koninklijke Nederlandse Akademie Van Wetenschappen | Transduction Buffer |
| ES2746805T3 (es) | 2013-12-12 | 2020-03-06 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo |
| WO2016009017A1 (en) * | 2014-07-16 | 2016-01-21 | Institut Gustave-Roussy | Combination of oncolytic virus with immune checkpoint modulators |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| EP3256156B1 (en) | 2015-02-13 | 2025-02-12 | Transgene | Immunotherapeutic vaccine and antibody combination therapy |
| US10639366B2 (en) | 2015-02-25 | 2020-05-05 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| KR20180006916A (ko) | 2015-04-17 | 2018-01-19 | 메모리얼 슬로안-케터링 캔서 센터 | 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도 |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| FR3042121A1 (fr) * | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| WO2017106129A1 (en) | 2015-12-16 | 2017-06-22 | Merck Sharp & Dohme Corp. | Anti-lag3 antibodies and antigen-binding fragments |
| US11612653B2 (en) * | 2016-01-08 | 2023-03-28 | Taiho Pharmaceutical Co., Ltd. | Anti-tumor agent containing immunomodulator, and antitumor effect potentiator |
| AU2017222686B2 (en) | 2016-02-25 | 2021-12-23 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy |
| KR20180130500A (ko) | 2016-02-25 | 2018-12-07 | 메모리얼 슬로안 케터링 캔서 센터 | 인간 flt3l을 발현하는 재조합 mva 또는 mvaδe3l 및 고형 종양에 대한 면역요법제로서 그의 용도 |
| EP3430148A4 (en) * | 2016-03-18 | 2020-01-01 | Nantcell, Inc. | MULTIMODAL VECTOR FOR DENDRITIC CELL INFECTION |
| EP3848393A1 (en) | 2016-05-18 | 2021-07-14 | Boehringer Ingelheim International GmbH | Antibody molecules for cancer treatment |
| US11602554B2 (en) | 2016-12-08 | 2023-03-14 | City Of Hope | P53-targeting vaccines and pd-1 pathway inhibitors and methods of use thereof |
| EP3621646A4 (en) | 2017-05-12 | 2021-06-02 | Memorial Sloan Kettering Cancer Center | VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY |
| JP7469225B2 (ja) | 2017-06-15 | 2024-04-16 | キャンサー アドヴァンシーズ インク． | 腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法 |
| US12150978B2 (en) * | 2017-06-15 | 2024-11-26 | Cancer Advances Inc. | Compositions and methods for preventing tumors and cancer |
| US11273211B2 (en) * | 2017-08-24 | 2022-03-15 | Bavarian Nordic A/S | Combination therapy for treating cancer with an intravenous administration of a recombinant MVA and an antibody |
| WO2019090343A1 (en) * | 2017-11-06 | 2019-05-09 | Memorial Sloan Kettering Cancer Center | Heat-inactivated vaccinia virus as a vaccine immune adjuvant |
| WO2019120269A1 (zh) * | 2017-12-22 | 2019-06-27 | 江苏恒瑞医药股份有限公司 | Lag-3抗体药物组合物及其用途 |
| CN116162654A (zh) | 2018-09-15 | 2023-05-26 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫疗法的重组痘病毒 |
| JP7484717B2 (ja) * | 2018-09-26 | 2024-05-16 | アステラス製薬株式会社 | 腫瘍溶解性ワクシニアウイルスと免疫チェックポイント阻害剤との併用によるがん療法並びにこれに用いるための医薬組成物及び組合せ医薬 |
| AU2019354101B2 (en) * | 2018-10-05 | 2026-02-19 | Bavarian Nordic A/S | Combination therapy for treating cancer with an intravenous administration of a recombinant MVA and an immune checkpoint antagonist or agonist |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| EP4031573A1 (en) | 2019-09-20 | 2022-07-27 | Transgene | Combination of a poxvirus encoding hpv polypeptides and il-2 with an anti-pd-l1 antibody |
| AU2020385683A1 (en) | 2019-11-18 | 2022-06-30 | Janssen Biotech, Inc. | Vaccines based on mutant CALR and JAK2 and their uses |
| TR202005738A1 (tr) * | 2020-04-10 | 2021-10-21 | Hacettepe Ueniversitesi Rektoerluek | Küçük hücreli̇ akci̇ğer kanseri̇nde cd44+ cd90+ kanser kök hücreleri̇ni̇n i̇ndükledi̇ği̇ tim-3 ve lag-3 reseptörünün hedeflenmesi̇ |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN115536749A (zh) * | 2021-06-29 | 2022-12-30 | 三生国健药业（上海）股份有限公司 | 三特异性抗体、其制备方法和用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2261989C (en) * | 1996-07-25 | 2008-09-30 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
| EP1292694A2 (en) * | 2000-06-15 | 2003-03-19 | The Government of the United States of America, as represented by the Secretary Department of Health and Human Services | A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
| EP1518932A1 (en) * | 2003-09-29 | 2005-03-30 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Modified vaccinia virus Ankara (MVA) mutant and use thereof |
| GB0706912D0 (en) * | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel viral vaccines |
| BRPI0919377A2 (pt) * | 2008-09-26 | 2016-09-27 | Dana Farber Cancer Inst Inc | anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento |
| CN102281897A (zh) * | 2008-10-31 | 2011-12-14 | T·S·顾巴 | 通过机械破坏表皮进行痘病毒载体的疫苗接种 |
| EP2482849B1 (en) * | 2009-09-30 | 2018-06-06 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| AU2011281982B2 (en) * | 2010-07-20 | 2015-12-17 | Bavarian Nordic A/S | Method for harvesting expression products |
| US9212224B2 (en) * | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
-
2014
- 2014-10-31 CN CN201480060569.5A patent/CN105744950A/zh active Pending
- 2014-10-31 US US15/034,496 patent/US20160271239A1/en not_active Abandoned
- 2014-10-31 WO PCT/US2014/063516 patent/WO2015069571A1/en not_active Ceased
- 2014-10-31 KR KR1020227010325A patent/KR102395820B1/ko active Active
- 2014-10-31 AU AU2014347004A patent/AU2014347004B2/en active Active
- 2014-10-31 CA CA2928199A patent/CA2928199C/en active Active
- 2014-10-31 EP EP14803277.4A patent/EP3065770B1/en active Active
- 2014-10-31 JP JP2016552257A patent/JP6535337B2/ja active Active
- 2014-10-31 NZ NZ719232A patent/NZ719232A/en unknown
- 2014-10-31 KR KR1020167011924A patent/KR20160070095A/ko not_active Ceased
- 2014-10-31 RU RU2016122035A patent/RU2714142C2/ru active
- 2014-10-31 DK DK14803277.4T patent/DK3065770T3/da active
-
2016
- 2016-04-20 IL IL245219A patent/IL245219B/en active IP Right Grant
-
2021
- 2021-03-18 US US17/205,634 patent/US20210205429A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016537417A5 (enExample) | ||
| RU2016122035A (ru) | Комбинированное лекарственное средство для лечения рака с использованием поксвируса, экспрессирующего опухолевый антиген, и антагониста и/или агониста ингибитора имунной контрольной точки | |
| JP2017515841A5 (enExample) | ||
| JP2017515837A5 (enExample) | ||
| Chen et al. | SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges | |
| Hodge et al. | The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors | |
| JP2016513640A5 (enExample) | ||
| CY1123688T1 (el) | Μεθοδοι για τη θεραπευτικη αντιμετωπιση ογκων χρησιμοποιωντας αμφιειδικο αντισωμα cd3xcd20 | |
| RU2016148311A (ru) | Комбинированная терапия для лечения рака с помощью рекомбинантного поксвируса, экспрессирующего опухолевый антиген, и антагониста или агониста молекулы иммунной контрольной точки | |
| JP2012524075A5 (enExample) | ||
| BR112018068748A2 (pt) | composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto | |
| MX2021005560A (es) | Terapia para el tratamiento del cancer con administracion intratumoral y/o intravenosa de un virus vaccinia ankara (mva) recombinante que codifica ligando 4-1bbl (cd137l) y/o ligando del cumulo o grupo de diferenciacion 40 (cd40l). | |
| MX2020001856A (es) | Terapia de combinacion para tratar el cancer con administracion intravenosa de un virus vaccinia ankara modificado (mva) recombinante y un anticuerpo. | |
| MX377144B (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer. | |
| JP2011500718A5 (enExample) | ||
| WO2015103438A3 (en) | Oncolytic virus adjunct therapy with agents that increase virus infectivity | |
| JP2018522822A5 (enExample) | ||
| JP2015506376A5 (enExample) | ||
| WO2016051398A8 (en) | Patient-specific immunotherapy for treating heterogeneous tumors | |
| HK1208629A1 (en) | Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency | |
| JP2015533376A5 (enExample) | ||
| JP2012021028A5 (enExample) | ||
| JP2015529676A5 (enExample) | ||
| CL2021000532A1 (es) | Vacunas peptídicas | |
| JP2019532047A5 (enExample) |